Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.31 |
| ▸ | STK25 | O00506 | 1/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252806 | 0.93 | CDK2 (0.36) | CDK2CDK8CDK1TRPV1CCR5 | |
| SCHEMBL2254807 | 0.93 | CDK2 (0.37) | CDK2CDK8CDK1TRPV1MCHR1 | |
| SCHEMBL2255260 | 0.92 | CDK2 (0.36) | CDK2CDK8CDK1TRPV1MCHR1 | |
| SCHEMBL2251570 | 0.90 | CDK1 (0.35) | CDK2CDK8CDK1TRPV1MCHR1 | |
| SCHEMBL2252035 | 0.89 | CDK1 (0.35) | CDK2CDK8CDK1TRPV1MCHR1 | |
| SCHEMBL2255130 | 0.88 | GALR3 (0.40) | MCHR1GALR3RAB9ASYKPRKAA1 | |
| Hydrochloric Acid SCHEMBL1448990 | 0.87 | LTA4H (0.37) | CCR5MCHR1 | |
| SCHEMBL2251435 | 0.86 | CDK2 (0.38) | CDK2CDK8CDK1TRPV1CCR5 | |
| SCHEMBL2253885 | 0.84 | CDK2 (0.37) | CDK2CDK8CDK1TRPV1CCR5 | |
| SCHEMBL4094280 | 0.84 | CDK2 (0.37) | CDK2CDK8CDK1TRPV1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | claimed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | CXCR3, CCR5, HLA-DRB1 | CDK2 641/4885CDK8 590/4885CDK1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.